Contribution
The hon. Member raises a very important point: this is a tragedy that has gone on for many years. I have to say that if we look at past performance, I have no confidence going forward. That is why I will ask to meet the Minister. Let us meet the MHRA to get the confidence that the hon. Member and his constituents need and want. I am pleased to see colleagues here today who will talk passionately—as he just did—on behalf of those who have suffered as a result of those medical scandals.
I do not want to repeat the litany of serious concerns I raised in the debate last year. Instead, I want to use my time today to highlight a specific and tragic case that lays out the human cost of the MHRA’s utter incompetence. In spring 2022, an 80-year-old mother with advanced Alzheimer’s, who was living in a care home in my constituency, received the Moderna covid-19 vaccine booster. She became ill the following day with a very high fever, severe and repeated vomiting, and hypoactive delirium, which is very serious for those with dementia. She deteriorated rapidly and subsequently died. There were reports of mass serious adverse reactions in the same care home after the booster was given, and a second related death.
Did the MHRA investigate? No. Did it respond fully to the family’s subsequent complaint? No. Did the MHRA review why the vaccine was approved for frail and elderly people, despite them being absent or under-represented in clinical trials? No. To quote from Moderna’s risk management plan,
“frail subjects with unstable health conditions and co-morbidities”,
including chronic neurological diseases, were identified as “Missing Information”. Why was the MHRA not honest about the woeful lack of safety evidence for using Moderna in the frail and elderly care home cohort?
My constituent’s son and daughter have pulled together the most extraordinary dossier of evidence, not just about their mother’s case but the wider issues it highlights about how drugs are assessed and approved for the elderly, and how safety signals were ignored and dismissed. They have basically done the MHRA’s job for them. Their vaccine damage payment scheme application prompted an investigation that amassed 944 pages of detailed medical evidence. It resulted in a successful claim, but the MHRA has still done nothing. In July this year, the family lodged a formal complaint about the MHRA’s handling of their mother’s case. The all-party parliamentary group on pandemic response and recovery, which I co-chair with the hon. Member for Blackley and Middleton South (Graham Stringer), supported that complaint. To date, the family has still not had a reply to the complaint.
The APPG did receive a reply from the Minister, though I am sorry to say it was inadequate, failing to mention the frail elderly, recognise the family’s vaccine damage payment scheme judgment or any consideration of the individual case. He was keen to reiterate that patient safety is the MHRA’s top priority, but those words mean nothing if they cannot be backed up with meaningful action.
This case is not an isolated one. It exemplifies the problems that I and other Members have raised repeatedly. In February 2024, our APPG, together with more than two dozen cross-party colleagues, wrote to the Health and Social Care Committee urging a thorough, wide-ranging investigation into the MHRA. We described the agency as being at “the heart of…endemic failings” that continue to put patients at serious risk. Those failings include deficiencies in the yellow card scheme, inadequate post-marketing surveillance, conflicts of interest, lack of transparency and a failure to scrutinise and act promptly on data safety concerns.
What happened to my constituent sadly aligns with those long-standing concerns. The MHRA did not properly evaluate or respond to the cluster of adverse events in that care home, where the residents were highly vulnerable. The MHRA seems happily to write off adverse reactions in the elderly as a mere temporal coincidence, yet the events in this case should have triggered rigorous investigation.
Comorbidities, frailty, physiological decline and multiple medications mean that care home residents are more susceptible to adverse effects. The MHRA is supposed to uphold the guidelines in the good pharmacovigilance practices documents, which stress the importance of monitoring the elderly population, due to increased risk factors. We see no evidence of that in relation to this case.
We will hear over the course of this debate how MHRA has failed many more patient groups, which have suffered life-changing injury or death due to other drugs or devices. I hope that will help to focus the Minister’s mind to act and find solutions. The human cost to patients and the financial burden on the healthcare system are substantial. Failure to act will lead only to more harm and further damage to public trust.